Incidence of chronic kidney disease stage 5 treated in south-eastern Algeria

##plugins.themes.academic_pro.article.sidebar##

Published Jun 28, 2024
https://doi.org/10.62438/tunismed.v102i7.4785
Download
PDF
Vol. 102 No. 7 (2024): Tunis Med jul 2024

##plugins.themes.academic_pro.article.main##

Nassim Meguellati
Department of Nephrology, Military Regional University Hospital of Constantine, Algeria
https://orcid.org/0009-0006-6161-063X
Nacereddine Regaiguia
Department of Nephrology, Military Regional University Hospital of Constantine, Algeria
Taher Rayane
University Benyoucef Benkhedda - Faculty of Medicine Algiers, Algeria.
Younes Boulahia
Department of Nephrology,Central Army Hospital Alger, Algeria.
Mahmoud Chiad
Department of Nephrology, Central Army Hospital Alger, Algeria.
Messaoud Saidani
Department of Nephrology, Beni Messous University Hospital, Alger,Algeria
Mohamed Tayeb Saadi
Department of Epidemiology and Preventive Medicine , Regional University Military Hospital of Constantine , Algeria
Mustapha Hanba
Department of Epidemiology and Preventive Medicine, Military Regional University Hospital of Oran, Algeria

Abstract

Introduction: Chronic kidney disease (CKD) stage 5 is a common pathology, the increase in its incidence and prevalence has been noted worldwide. In Algeria, few studies have been done on the epidemiology of chronic kidney disease, the real extent of its incidence in southern Algeria remains unknown.


Aim: To determine the incidence in 2017 of chronic kidney disease stage 5 treated by renal replacement in southeastern Algeria.


Method: During our multicenter, prospective longitudinal regional study, from January 1, 2017 to December 31, 2017, all resident incident cases of CKD stage 5 treated in the region by renal replacement were recruited.


Results: The crude incidence of stage 5 CKD treated in 2017 in southeastern Algeria was 75 pmh. The age-standardized incidence rate was 100 pmh, with a male predominance, a M/F sex ratio of 1.59. The average age of incident cases was 48.50 ± 19.12 years. The incidence varies by age group and by wilaya. Diabetes (26.7%) and hypertensive nephropathy (22.6%) represent almost half of the cases and primary glomerulonephritis represents 5.9%.


Conclusion: CKD stage 5 treated, due to its high incidence in Algeria, with large geographical variations, represents a major public health challenge. It mainly affects young people. Diabetes and high blood pressure represent the two main causes, encouraging prevention efforts to be focused on hypertensives and diabetics in high-risk wilayas.

Keywords:

dialysis, incidence, chronic kidney disease stage 5.

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. El Nahas AM, Bello AK. Chronic kidney disease: the global challenge. The Lancet. 2005;365(9456):331-40.
  2. Stengel B. L’insuffisance rénale chronique: une épidémie? La Presse Médicale. 2011;40(11):1020-7.
  3. Boulahia Y, Djaballah A, Azzouz R, Kerbouz N, Chiad M, Iftène D. Urémie terminale traitée chez l’adulte dans la wilaya d’Alger en 2004, 2005 et 2006. Nephrologie & therapeutique. 2011;5(7):422.
  4. Levey AS, Coresh J. Chronic kidney disease. The Lancet. 2012;379(9811):165-80.
  5. Naicker S. End-stage renal disease in Sub-Saharan Africa. Kidney international supplements. 2013;3(2):161-3.
  6. R.E.I.N. Rapport annuel 2016 - Réseau Épidémiologie et information en néphrologie. Agence de la biomédecine. 2016.
  7. USRDS. End-stage Renal Disease (ESRD) in the United States, Chapter 11: International Comparisons. United States Renal Data System 2018.
  8. Yamagata K. Trends in the incidence of kidney replacement therapy: comparisons of ERA, USRDS and Japan registries. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2023;38(4):797-9.
  9. Huijben JA, Kramer A, Kerschbaum J, de Meester J, Collart F, Arévalo OLR, et al. Increasing numbers and improved overall survival of patients on kidney replacement therapy over the last decade in Europe: an ERA Registry study. Nephrology Dialysis Transplantation. 2023;38(4):1027-40.
  10. Yamagata K, Yagisawa T, Nakai S, Nakayama M, Imai E, Hattori M, et al. Prevalence and incidence of chronic kidney disease stage G5 in Japan. Clinical and experimental nephrology. 2015;19:54-64.
  11. Meguellati N, Rayane T, Boulahia Y, Saidani M, Atik A, Saidi A, et al. Épidémiologie de la maladie rénale chronique stade V traitée dans le Sud-Est algérien : étude prospective de 2016 à 2018.2023.
  12. Rayane T. Données sur la prise en charge de l'insuffisance rénale chronique terminale. Congrès National de Néphrologie 25, 26 & 27 Novembre 2016 SANDT. 2016.
  13. Atik A, Tehir M, Khemri D, Bougroura A, Ramdani B, Bayahia R, et al. Transplantation rénale au Maghreb: état des lieux et perspectives. Nephrologie & therapeutique. 2017;13(5):291.
  14. ONS. Démographie algérienne 2017. Office national des statistiques. 2018;N°816.
  15. MSPRH. Projection du développement du secteur de la santé : Perspective décennale. Ministère de la sante de la population et de la reforme hospitalière. 2003.
  16. Institut National de Santé Publique A. Enquête Nationale Santé TAHINA. 2007.
  17. Labidi J, Harzallah A, Kaab BB, Mami I, Agrebi S, Azzabi A, et al. Prevalence of chronic kidney disease in Tunisian diabetics: the TUN-CKDD survey. BMC nephrology. 2024;25(1):67.
  18. Bouhabel A, Laib Z, Hannache K, Aberkane A. Traitement de suppléance rénale par hémodialyse à Constantine (Algérie): état des lieux. Nephrologie & therapeutique. 2014;10(1):39-43.
  19. USRDS. US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States. 2019.
  20. Registry E-E. The European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2017. 2019.
  21. R.E.I.N. Rapport annuel 2017 - Réseau Épidémiologie et information en néphrologie. Agence de la biomédecine. 2019.
  22. Registry UR. The Twentieth Annual Report. Annual Report 2017. 2017;20th.
  23. ANZDATA Registry. 41st Report, Chapter 1: Incidence of End Stage Kidney Disease. Australia and New Zealand Dialysis and Transplant Registry, Adelaide, Australia. ANZDATA Registry. 2018.
  24. Davids R, Jardine T, Marais N, Jacobs J. South African Renal Registry Annual Report 2016. 2018.
  25. Kazes I, Béchade C, Lobbedez T, Couchoud C, Lassalle M. Incidence de la maladie rénale chronique stade 5 traitée par suppléance et contexte d’initiation de la dialyse. Nephrologie & therapeutique. 2022;18(5, Supplement 2):18/5S-e9-/5S-e4.
  26. Couchoud C, Guihenneuc C, Bayer F, Stengel B, registry R. The timing of dialysis initiation affects the incidence of renal replacement therapy. Nephrology Dialysis Transplantation. 2010;25(5):1576-8.
  27. Couchoud C, Guihenneuc C, Bayer F, Lemaitre V, Brunet P, Stengel B, et al. Medical practice patterns and socio-economic factors may explain geographical variation of end-stage renal disease incidence. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2012;27(6):2312-22.
  28. Kihal-Talantikite W, Deguen S, Padilla C, Siebert M, Couchoud C, Vigneau C, et al. Spatial distribution of end-stage renal disease (ESRD) and social inequalities in mixed urban and rural areas: a study in the Bretagne administrative region of France. Clinical kidney journal. 2015;8(1):7-13.
  29. Occelli F, Deram A, Genin M, Noel C, Cuny D, Glowacki F, et al. Mapping end-stage renal disease (ESRD): spatial variations on small area level in northern France, and association with deprivation. PloS one. 2014;9(11):e110132.
  30. Desmarets M, Ayav C, Diallo K, Bayer F, Imbert F, Sauleau EA, et al. Fine-scale geographic variations of rates of renal replacement therapy in northeastern France: Association with the socioeconomic context and accessibility to care. PloS one. 2020;15(7):e0236698.
  31. Couchoud C, Guihenneuc C, Bayer F, Lemaitre V, Brunet P, Stengel B. Medical practice patterns and socio-economic factors may explain geographical variation of end-stage renal disease incidence. Nephrology Dialysis Transplantation. 2012;27(6):2312-22.
  32. Kihal-Talantikite W, Deguen S, Padilla C, Siebert M, Couchoud C, Vigneau C, et al. Spatial distribution of end-stage renal disease (ESRD) and social inequalities in mixed urban and rural areas: a study in the Bretagne administrative region of France. Clinical kidney journal. 2015;8(1):7-13.
  33. Occelli F, Deram A, Génin M, Noël C, Cuny D, Glowacki F, et al. Mapping end-stage renal disease (ESRD): spatial variations on small area level in northern France, and association with deprivation. PloS one. 2014;9(11):e110132.
  34. Chatelet V, Bayat S, Driollet B, Merle V, Moranne O, Lassalle M. REIN: un outil au service de l’éclairage des inégalités en santé. Nephrologie & therapeutique. 2022;18(5):18/5S-e40-18/5S-e43.
  35. Asserraji M, Maoujoud O, Belarbi M, Oualim Z. Profil épidémiologique de l'insuffisance rénale terminale à l'hôpital Militaire de Rabat, Maroc. The Pan African medical journal. 2015;20.
  36. Moukeh G, Yacoub R, Fahdi F, Rastam S, Albitar SJSJoKD, Transplantation. Epidemiology of hemodialysis patients in Aleppo city. 2009;20(1):140.
  37. Ghonemy T, Farag S, Soliman S, El-okely A, El-hendy Y. Epidemiology and risk factors of chronic kidney disease in the El-Sharkia Governorate, Egypt. 2016;27(1):111-7.
  38. Yamagata K, Takahashi H, Suzuki S, Mase K, Hagiwara M, Shimizu Y, et al. Age distribution and yearly changes in the incidence of ESRD in Japan. American journal of kidney diseases. 2004;43(3):433-43.
  39. USRDS. End-stage Renal Disease (ESRD) in the United States. Chapter 1: Incidence, Prevalence, Patient Characteristics, and Treatment Modalities. United States Renal Data System 2018.